long intergenic non-protein coding RNA 1007Genealiases: []
Q-omics provides the consensus-scored LINC01007 profile across patient tissues and cancer cell-line models. LINC01007 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, LINC01007 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, LINC01007 RNA expression shows 7,271 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, KIRP, and GBM as cancer lineages where LINC01007 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01007 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01007 survival associations across molecular data types. LINC01007 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01007 RNA expression–survival associations across cancer types. High LINC01007 expression shows unfavorable associations in THCA, LUAD, DLBC, UCEC and LIHC, but favorable associations in LGG. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for LINC01007 RNA expression.
This table summarizes LINC01007 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01007. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01007 shows lower tumor expression in PRAD and higher tumor expression in KIRP and COAD. The KIRP box plot shows higher LINC01007 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .001).
This table shows molecular features associated with LINC01007 in patient tissues and cancer cell lines. In patient samples, LINC01007 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
